Mediator kinase-regulated transcriptional reprogramming

A broad therapeutic target

  • Thu 10 Feb 22

    13:00 - 14:00

  • Colchester Campus

    STEM 3.1

  • Event speaker

    Professor Igor Roninson

  • Event type

    Lectures, talks and seminars

  • Event organiser

    Life Sciences, School of

  • Contact details

    Dr Charalampos (Babis) Rallis

CDK8/19 Mediator kinase plays a unique role in transcriptional regulation: it potentiates the induction of gene expression by many signal-responsive transcription factors with little or no effect on the basal expression of signal-responsive genes.

Mediator kinase has been implicated in embryonic development and in many pathological processes, such as cancer metastasis and resistance to different types of therapy, inflammatory responses and pathological tissue remodeling.

Selective inhibitors of CDK8/19 are being developed for several types of cancer and other diseases that involve transcriptional reprogramming.


Professor Igor Roninson received his PhD and postdoctoral training at the Massachusetts Institute of Technology. He served on the faculty at the University of Illinois at Chicago from 1984-2003, before becoming Director of Cancer Center at Ordway Research Institute in Albany, NY. In 2011, he joined the University of South Carolina (USC) College of Pharmacy as Endowed Chair in Translational Cancer Therapeutics. Since 2014, he has directed NIH-supported interdisciplinary Center for Targeted Therapeutics. He is also the Founder and President of Senex Biotechnology, Inc., a drug discovery and development company.

Dr. Roninson has authored more than 175 articles (H factor 79) and is an inventor on 47 issued US patents. His accomplishments include the development of the in-gel DNA renaturation technique for the detection and cloning of amplified genes, isolation and characterization of the MDR1 (ABCB1) multidrug resistance gene (the first identified mammalian ABC transporter), the methodology for using RT-PCR to measure gene expression in clinical samples, the development of the genetic suppressor element (GSE) methodology for function-based identification of genes mediating various phenotypes, the discovery of chemotherapy-induced senescence in tumor cells, identification of CDK8/19 as a mediator of paracrine tumor-promoting activities of damaged and senescent cells and the development of the first selective CDK8/19 inhibitors to enter clinical trials.

How to attend

This seminar is being held in person in STEM 3.1 (STEM Centre on Square 1, Colchester campus). You can also watch via Zoom (meeting ID: 925 4561 0277)

If you have any queries about this seminar please email Dr Charalampos (Babis) Rallis (c.rallis@essex.ac.uk).

Related events